This activity is intended for BCACPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This series will feature succinct commentaries about practice-changing evidence through a series of podcasts, articles. online panel discussions, and polls. This module consists of 4 activities and offers up to 2 hours of continuing pharmacy education and/or recertification credit. These activities are produced in conjunction with iForumRx and are part of the APhA professional development program for BCACP recertification approved by BPS.
Additional Modules can be found here:
At the completion of this activity, the participant will be able to:
Will oral semaglutide PIONEER the way to lower CV risk?
LO1: List the antidiabetic medications that have proven cardiovascular benefit. (Knowledge)
LO2: Compare the cardiovascular related outcomes in the PIONEER 6 trial that evaluated oral semaglutide to the SUSTAIN 6 trial involving subcutaneous semaglutide. (Evaluation)
LO3: Apply the findings of the PIONEER 6 trial to a patient scenario. (Application)
Secondary Stroke Prevention in A-Fib: Do DOACs PROSPER in High-Risk Patients?
LO1: Summarize key clinical outcomes regarding the use of direct oral anticoagulants versus warfarin for secondary stroke prevention in elderly patients with atrial fibrillation
LO2: Apply key findings from the PROSPER study to a patient case related to the secondary prevention of stroke in atrial fibrillation
LO3: Identify laboratory values for appropriate monitoring of direct oral anticoagulants
Are older adults with heart failure self-care aware?
LO1: Understand the correlation between reported self-care behaviors and actual ability, as well as how performance limitations of the aging population living with heart failure correlates with 1-year readmission rate and mortality
LO2: Classify patient self-care performance ability using reported self-care behaviors, actual ability, and the European Heart Failure Self-care Behaviour Scale (EHFScBS)
LO3: Assess a participant’s self-care performance ability with objective tools utilized in the FRAIL-HF study
Management of reduced ejection fraction heart failure and use of SGLT2 inhibitors.
LO1: Apply results of the DAPA-HF trial to a specific patient-case scenario.
LO2: Develop patient-specific, evidence-based treatment, monitoring, and follow-up plans for patients with reduced ejection heart failure.
LO3: Discuss the benefits and risks associated with the sodium-glucose cotransporter 2 (SGLT2) inhibitors class of antihyperglycemic agents.
Activity type: Application-based
Target Audience: Pharmacists
Learning level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 2 contact hours of CPE credit (0.2 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-19-299-H04-P.
To obtain 2 contact hours of CPE credit (0.2 CEUs) for Evidence-Based Practice Module 5, complete the learning activities, assessment with a grade of 71% or better, and evaluation questions.
Per Board of Pharmacy Specialties (BPS) requirements, you will have one opportunity to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a second time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
You do not need to complete assessment in one sitting. Once successfully completed, you will be able to claim credit. Participants will need to have a valid APhA (pharmacist.com) username and password, as well as a CPE Monitor account to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
Initial release date: December 30, 2019
Expiration date: December 30, 2022
Evidence-Based Practice Module 5 is an online educational activity for pharmacists developed by the American Pharmacists Association.
APhA’s editorial staff declares no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-19-299-H04-P||0.2 CEUs||December 30, 2019 - December 30, 2022|
|0202-0000-19-299-H04-P||2 Hours||December 30, 2019 - December 30, 2022|